Related Experiment Video
Updated: Feb 26, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Nerve/Glial Antigen 2: A Novel Target for Anti-Tumor Therapy in Colorectal Cancer
Cem Cengiz1, Safak Bulut, A Sedat Boyacioglu
1Department of Gastroenterology, TOBB University of Economics and Technology, Ankara, Turkey.
Background/Aims:
To identify cell surface markers selectively expressed by tumor cells and tumor vasculature is the current goal for tumor therapy. One such marker is nerve/glial antigen 2 (NG2), which is a transmembrane glycoprotein. We aimed to investigate the expression of NG2 in colorectal cancer (CRC) and its association with clinicopathological parameters.
Methods:
Immunohistochemical staining of NG2, vascular endothelial growth factor, and CD34 in 65 patients diagnosed with CRC over a 5-year period was performed. NG2 expression in both tumor cells and tumor vasculature was scored according to the German Reactive Scoring System. The association between NG2 and patient and tumor characteristics was analyzed.
Results:
NG2 was expressed by tumor cells in 56.9%, tumor vasculature in 43%, and simultaneously by both in 27.6% of the cases. Tumor cell NG2 was more common in elderly patients (p = 0.023) and vascular NG2 was associated with better tumor differentiation (p = 0.035). Notably, vascular NG2 was expressed in half of the patients with left colon cancer, although it was not expressed in a majority of those with right colon cancer (50.9 vs. 17.7%, p = 0.041).
Conclusion:
Both tumor cell and vascular NG2 expression were shown to be present in a significant number of patients with CRC and this makes NG2 a double target for anti-tumor therapies. Such therapies might be more effective for elderly patients with well-differentiated left colon cancer.
Insights
Nerve/glial antigen 2 (NG2) is expressed by tumor cells and vasculature in colorectal cancer (CRC). This dual expression suggests NG2 as a potential therapeutic target, particularly for elderly patients with well-differentiated left colon cancer.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Targeting specific cell surface markers on tumor cells and vasculature is crucial for effective cancer therapy.
- Nerve/glial antigen 2 (NG2), a transmembrane glycoprotein, is a potential target due to its selective expression.
- Investigating NG2 expression in colorectal cancer (CRC) is essential for understanding its therapeutic potential.
Purpose of the Study:
- To determine the expression patterns of NG2 in colorectal cancer (CRC) tissues.
- To analyze the association between NG2 expression and clinicopathological parameters in CRC patients.
- To evaluate NG2 as a potential dual target for anti-tumor therapies in CRC.
Main Methods:
- Immunohistochemical staining was performed on 65 CRC patient samples.
- NG2, vascular endothelial growth factor, and CD34 expression were assessed.
- NG2 expression levels in tumor cells and vasculature were scored and correlated with clinicopathological data.
Main Results:
- NG2 was expressed by tumor cells in 56.9% and tumor vasculature in 43% of CRC cases.
- Simultaneous expression of NG2 in both tumor cells and vasculature was observed in 27.6% of patients.
- Tumor cell NG2 correlated with older patient age, while vascular NG2 associated with better tumor differentiation and was more prevalent in left-sided colon cancer.
Conclusions:
- NG2 is present on both tumor cells and vasculature in a significant proportion of CRC patients, presenting a dual therapeutic target.
- NG2-targeted therapies may offer enhanced efficacy in elderly patients with well-differentiated left colon cancer.
- Further research into NG2-targeted strategies for CRC is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:27Tumor Immunotherapy